Enliven Therapeutics
ELVN
NASDAQ
IPO2023
about ELVN
Enliven Therapeutics is a biotechnology company dedicated to developing innovative gene therapy treatments for rare diseases, with its lead candidate Elnaferon targeting lysosomal storage disorders such as Gaucher disease and Niemann-Pick disease.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $23.58 | $29.98 | $23.27 | $1.4B | 3.32M |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| -$0.32 | n/a | n/a | 0% | 0% | 0% |